HR+ breast cancer

Clinical trials for HR+ breast cancer explained in plain language.

Never miss a new study

Get alerted when new HR+ breast cancer trials appear

Sign up with your email to follow new studies for HR+ breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 3 Not yet recruiting 3 Terminated 1

New cancer drug BLU-222 tested in early trial – but study stopped early

Disease control Stopped early

This early-phase trial tested a new drug called BLU-222, alone or with other medicines, in about 50 people with advanced solid tumors (including certain breast, ovarian, and stomach cancers). The goal was to find a safe dose and see if it shrinks tumors. However, the study was te…

Matched conditions: HR+ BREAST CANCER

Phase 1 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control

Last updated Jun 27, 2026 08:00 UTC

HR+ breast cancer

Get alerted when new HR+ breast cancer trials appear

New cancer drug BLU-222 tested in early trial – but study stopped early